Please wait while the formulary information is being retrieved.
Drug overview for ASTEPRO ALLERGY (azelastine hcl):
Generic name: azelastine HCl (AY-ze-LAS-teen)
Drug class: Nasal Antihistamines
Therapeutic class: Respiratory Therapy Agents
Azelastine is a histamine H1-receptor antagonist.
No enhanced Uses information available for this drug.
Generic name: azelastine HCl (AY-ze-LAS-teen)
Drug class: Nasal Antihistamines
Therapeutic class: Respiratory Therapy Agents
Azelastine is a histamine H1-receptor antagonist.
No enhanced Uses information available for this drug.
DRUG IMAGES
No Image Available
The following indications for ASTEPRO ALLERGY (azelastine hcl) have been approved by the FDA:
Indications:
Perennial allergic rhinitis
Seasonal allergic rhinitis
Vasomotor rhinitis
Professional Synonyms:
Atopic rhinitis
Intermittent allergic rhinitis
Non-seasonal allergic rhinitis
Periodic runny nose
Seasonal allergy
Indications:
Perennial allergic rhinitis
Seasonal allergic rhinitis
Vasomotor rhinitis
Professional Synonyms:
Atopic rhinitis
Intermittent allergic rhinitis
Non-seasonal allergic rhinitis
Periodic runny nose
Seasonal allergy
The following dosing information is available for ASTEPRO ALLERGY (azelastine hcl):
The manufacturer preferentially labels the dosage and concentration of azelastine hydrochloride in terms of the hydrochloride salt.
No enhanced Administration information available for this drug.
| DRUG LABEL | DOSING TYPE | DOSING INSTRUCTIONS |
|---|---|---|
| ASTEPRO ALLERGY 205.5MCG SPRAY | Maintenance | Adults spray 1 spray (205.5 mcg) in each nostril by intranasal route 2 times per day |
| DRUG LABEL | DOSING TYPE | DOSING INSTRUCTIONS |
|---|---|---|
| AZELASTINE 0.15% NASAL SPRAY | Maintenance | Adults spray 1 spray (205.5 mcg) in each nostril by intranasal route 2 timesper day |
The following drug interaction information is available for ASTEPRO ALLERGY (azelastine hcl):
There are 0 contraindications.
There are 2 severe interactions.
These drug interactions can produce serious consequences in most patients. Actions required for severe interactions include, but are not limited to, discontinuing one or both agents, adjusting dosage, altering administration scheduling, and providing additional patient monitoring. Review the full interaction monograph for more information.
| Drug Interaction | Drug Names |
|---|---|
| Radioactive Iodide/Agents that Affect Iodide SEVERITY LEVEL: 2-Severe Interaction: Action is required to reduce the risk of severe adverse interaction. MECHANISM OF ACTION: Many compounds can affect iodide protein binding and alter iodide pharmacokinetics and pharmacodynamics.(1) CLINICAL EFFECTS: Compounds that affect iodide pharmacokinetics and pharmacodynamics may impact the effectiveness of radioactive iodide.(1) PREDISPOSING FACTORS: Compounds that affect iodide pharmacokinetics and pharmacodynamics are expected to have the most impact during therapy using radioactive iodide. Diagnostic procedures would be expected to be impacted less. PATIENT MANAGEMENT: Discuss the use of agents that affect iodide pharmacokinetics and pharmacodynamics with the patient's oncologist.(1) Because indocyanine green contains sodium iodide, the iodine-binding capacity of thyroid tissue may be reduced for at least one week following administration. Do not perform radioactive iodine uptake studies for at least one week following administration of indocyanine green.(2) The manufacturer of iopamidol states administration may interfere with thyroid uptake of radioactive iodine and decrease therapeutic and diagnostic efficacy. Avoid thyroid therapy or testing for up to 6 weeks post administration of iopamidol.(3) DISCUSSION: Many agents interact with radioactive iodine. The average duration of effect is: anticoagulants - 1 week antihistamines - 1 week anti-thyroid drugs, e.g: carbimazole, methimazole, propylthiouracil - 3-5 days corticosteroids - 1 week iodide-containing medications, e.g: amiodarone - 1-6 months expectorants - 2 weeks Lugol solution - 3 weeks saturated solution of potassium iodine - 3 weeks vitamins - 10-14 days iodide-containing X-ray contrast agents - up to 1 year lithium - 4 weeks phenylbutazone - 1-2 weeks sulfonamides - 1 week thyroid hormones (natural or synthetic), e.g.: thyroxine - 4 weeks tri-iodothyronine - 2 weeks tolbutamide - 1 week topical iodide - 1-9 months (1) |
ADREVIEW, JEANATOPE, MEGATOPE, SODIUM IODIDE I-123 |
| Sodium Iodide I 131/Agents that Affect Iodide SEVERITY LEVEL: 2-Severe Interaction: Action is required to reduce the risk of severe adverse interaction. MECHANISM OF ACTION: Many compounds can affect iodide protein binding and alter iodide pharmacokinetics and pharmacodynamics.(1,2) CLINICAL EFFECTS: Compounds that affect iodide pharmacokinetics and pharmacodynamics may impact the effectiveness of radioactive iodide.(1,2) PREDISPOSING FACTORS: Compounds that affect iodide pharmacokinetics and pharmacodynamics are expected to have the most impact during therapy using radioactive iodide. Diagnostic procedures would be expected to be impacted less. PATIENT MANAGEMENT: Discuss the use of agents that affect iodide pharmacokinetics and pharmacodynamics with the patient's oncologist.(1,2) Because indocyanine green contains sodium iodide, the iodine-binding capacity of thyroid tissue may be reduced for at least one week following administration. Do not perform radioactive iodine uptake studies for at least one week following administration of indocyanine green.(3) The manufacturer of iopamidol states administration may interfere with thyroid uptake of radioactive iodine and decrease therapeutic and diagnostic efficacy. Avoid thyroid therapy or testing for up to 6 weeks post administration of iopamidol.(4) DISCUSSION: Many agents interact with radioactive iodine. The average duration of effect is: anticoagulants - 1 week antihistamines - 1 week anti-thyroid drugs, e.g: carbimazole, methimazole, propylthiouracil - 3-5 days corticosteroids - 1 week iodide-containing medications, e.g: amiodarone - 1-6 months expectorants - 2 weeks Lugol solution - 3 weeks saturated solution of potassium iodine - 3 weeks vitamins - 10-14 days iodide-containing X-ray contrast agents - up to 1 year lithium - 4 weeks phenylbutazone - 1-2 weeks sulfonamides - 1 week thyroid hormones (natural or synthetic), e.g.: thyroxine - 4 weeks tri-iodothyronine - 2 weeks tolbutamide - 1 week topical iodide - 1-9 months (1,2) |
HICON, SODIUM IODIDE I-131 |
There are 0 moderate interactions.
The following contraindication information is available for ASTEPRO ALLERGY (azelastine hcl):
Drug contraindication overview.
No enhanced Contraindications information available for this drug.
No enhanced Contraindications information available for this drug.
There are 0 contraindications.
There are 0 severe contraindications.
There are 1 moderate contraindications.
Clinically significant contraindication, where the condition can be managed or treated before the drug may be given safely.
| Moderate List |
|---|
| Drowsy |
The following adverse reaction information is available for ASTEPRO ALLERGY (azelastine hcl):
Adverse reaction overview.
No enhanced Common Adverse Effects information available for this drug.
No enhanced Common Adverse Effects information available for this drug.
There are 13 severe adverse reactions.
| More Frequent | Less Frequent |
|---|---|
| None. |
Cough |
| Rare/Very Rare |
|---|
|
Anaphylaxis Atrial fibrillation Blurred vision Bronchospastic pulmonary disease Hematuria Ocular pain Pruritus of skin Skin rash Stomatitis Tachycardia Urinary retention Visual changes |
There are 48 less severe adverse reactions.
| More Frequent | Less Frequent |
|---|---|
|
Drowsy Dysesthesia Dysgeusia Headache disorder |
Conjunctivitis Dizziness Epistaxis Fatigue Myalgia Nasal passage irritation Nausea Pharyngitis Rhinitis Sneezing Weight gain Xerostomia |
| Rare/Very Rare |
|---|
|
Acute cognitive impairment Aphthous stomatitis Chest pain Constipation Contact dermatitis Depression Diarrhea Dry eye Dyspnea Eczema Eye tearing Facial edema Flushing Folliculitis Furunculosis Gastroenteritis Glossitis Hyperkinesis Hypertension Hypoesthesia Increased appetite Lacerations Lesion of nasal mucosa Loss of sense of smell Nervousness Palpitations Paresthesia Parosmia Sleep disorder Symptoms of anxiety Toothache Vomiting |
The following precautions are available for ASTEPRO ALLERGY (azelastine hcl):
No enhanced Pediatric Use information available for this drug.
Contraindicated
Severe Precaution
Management or Monitoring Precaution
Contraindicated
| None |
Severe Precaution
| None |
Management or Monitoring Precaution
| None |
No enhanced Pregnancy information available for this drug.
No enhanced Lactation information available for this drug.
No enhanced Geriatric Use information available for this drug.
The following prioritized warning is available for ASTEPRO ALLERGY (azelastine hcl):
No warning message for this drug.
No warning message for this drug.
The following icd codes are available for ASTEPRO ALLERGY (azelastine hcl)'s list of indications:
| Perennial allergic rhinitis | |
| J31.0 | Chronic rhinitis |
| Seasonal allergic rhinitis | |
| J30.1 | Allergic rhinitis due to pollen |
| J30.2 | Other seasonal allergic rhinitis |
| Vasomotor rhinitis | |
| J30.0 | Vasomotor rhinitis |
Formulary Reference Tool